Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors.
Xenotransplantation
; 23(2): 151-8, 2016 03.
Article
en En
| MEDLINE
| ID: mdl-27028725
ABSTRACT
BACKGROUND:
Porcine endogenous retrovirus (PERV) is an endogenous retrovirus that poses a risk of iatrogenic transmission in the context of pig-to-human xenotransplantation. The lack of a means to control PERV infection in the context of pig-to-human xenotransplantation is a major concern in the field. In this study, we set out to evaluate the ability of currently licensed anti-HIV drugs, and other types of anti-retroviral compounds, to inhibit PERV infection in vitro.METHODS:
We used target cells stably expressing one of the known PERV viral receptors, an infectious molecular clone, PERV-A 14/220, and at least one drug from each class of anti-retroviral inhibitors as well as off-label drugs shown to have anti-viral activities. The susceptibility of PERV-A 14/220 LacZ to the anti-retroviral drugs was determined from infected cells by histochemical staining.RESULTS:
We extend the results of previous studies by showing that, in addition to raltegravir, dolutegravir is found to have a potent inhibitory activity against PERV replication (IC50 8.634 ±0.336 and IC50 3.06 ± 0.844 nM, respectively). The anti-HIV drug zidovudine (AZT) showed considerable anti-PERV activity with IC50 of 1.923 ±0.691 µM as well.CONCLUSIONS:
The study results indicate that some of the licensed anti-retroviral drugs may be useful for controlling PERV infection. However, the efficacy at nanomolar concentrations put forward integrase inhibitors as a drug that has the potential to be useful in the event that xenotransplantation recipients have evidence of PERV transmission and replication.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Virosis
/
Retrovirus Endógenos
/
Antirretrovirales
Límite:
Animals
Idioma:
En
Año:
2016
Tipo del documento:
Article